June 22, 2022

The MMS will continue to monitor developments related to the coronavirus (COVID-19) and the response by state and federal agencies. For current information, including updates from NEJM, visit the dedicated page on the MMS website: massmed.org/covid-19.

Practice Management

**Ordering information for Pfizer (6 months to 4 years old) and Moderna (6 months to 5 years old) vaccine formulations**

As a trusted source of medical advice, pediatric provider participation in the young pediatric population vaccination process is essential. Some vaccination options available to older pediatric patients, such as pharmacies, will not be available to the infant population. Massachusetts COVID-19 Vaccine Program (MCVP) enrolled provider sites may place orders for the new formulations of the COVID vaccine through the Massachusetts Immunization Information System (MIIS) beginning Monday, June 20. For guidance on how to place COVID-19 vaccine orders in the MIIS, please see mini-guide | Flu/COVID-19 order.

**Pfizer (maroon cap) - NDC 59267-0078-04**

- For 6 months to 4 years old.
- Vaccines will ship at -80°C, like all current Pfizer COVID-19 vaccines.
• Vaccines can be stored in the ultracold freezer for 12 months after manufacturer date and 10 weeks in the refrigerator. Do not store in the freezer.

Modern (blue cap) - NDC 80777-0279-99

• For 6 months to 5 years old.
• Vaccines will ship at -20°C, like all current Moderna COVID-19 vaccines.
• Vaccines can be stored in the freezer until the expiration date or in the refrigerator for 30 days.

Packaging configuration for both vaccine products is 10-dose vials in cartons of 10 vials with a minimum order quantity of 100 doses.

Resources:
• Vaccine Management Unit: Phone: (617) 983-6828
• MIIS Help Desk: Phone: (617) 983-4335/ Fax: (857) 323-8321

Public Health

Who to vaccinate this week

Everyone ages 6 months and older should receive a COVID-19 primary series vaccination for the prevention of COVID-19.

Everyone ages 5 years and older should receive at least 1 booster dose of COVID-19 vaccine if eligible (i.e., if a booster dose is FDA-approved or FDA-authorized for use in a specified population). Recommendations for booster dose(s) vary based on age, COVID-19 vaccine product, and immunocompetence.

The recommended schedule and use of each COVID-19 vaccine product vary by the age and immune status of the recipient. There are two vaccination schedules: one for people who are not moderately or severely immunocompromised and one for people who are moderately or severely immunocompromised.

KEY POINTS
COVID-19 vaccines currently approved or authorized by FDA are effective in preventing serious outcomes of COVID-19 disease, including severe disease, hospitalization, and death.

Janssen COVID-19 vaccine should only be used in limited situations; Pfizer-BioNTech or Moderna COVID-19 vaccines are preferred for primary and booster vaccination.

Efforts to increase the number of people in the United States who are up to date with their COVID-19 vaccines remain critical to preventing illness, hospitalizations, and deaths from COVID-19.

The clinical considerations provide additional information to healthcare professionals and public health officials on use of COVID-19 vaccines.

CDC resource, watch the next ACIP meeting

Centers for Disease Control and Prevention (CDC) at-a-glance vaccination schedule:
The CDC has produced a helpful two-page pdf showing COVID-19 vaccine recommendations based on primary series product, age, and immune status.

ACIP Meeting June 23
The Advisory Committee on Immunization Practices (ACIP) will be meeting to discuss recommendations for the recently authorized Moderna COVID-19 Vaccine for ages 6-17 years on Thursday, June 23. Find an agenda and link to webcast here.